rhuFab V2 (ranibizumab) — Competitive Intelligence Brief

rhuFab V2 (ranibizumab) (rhuFab V2 (ranibizumab)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF inhibitor. Area: Ophthalmology.

phase 3 VEGF inhibitor VEGF-A Ophthalmology Small molecule

Target snapshot

rhuFab V2 (ranibizumab) (rhuFab V2 (ranibizumab)) — Genentech, Inc.. Ranibizumab is a recombinant humanized monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A).

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
rhuFab V2 (ranibizumab) TARGET	rhuFab V2 (ranibizumab)	Genentech, Inc.	phase 3	VEGF inhibitor	VEGF-A
Ranibizumab plus Photodynamic therapy	Ranibizumab plus Photodynamic therapy	Illinois Retina Associates	marketed	Anti-VEGF monoclonal antibody fragment combined with photodynamic therapy	VEGF-A (ranibizumab component)
Ranibizumab (Lucentis)	Ranibizumab (Lucentis)	Greater Houston Retina Research	marketed	VEGF-A inhibitor (monoclonal antibody fragment)	VEGF-A (Vascular Endothelial Growth Factor A)
Ranibizumab and laser	Ranibizumab and laser	Fukushima Medical University	marketed	VEGF inhibitor (monoclonal antibody fragment) combined with laser photocoagulation	VEGF-A
ranibizumab PRN	ranibizumab PRN	Seoul National University Hospital	marketed	VEGF-A inhibitor monoclonal antibody fragment	VEGF-A (Vascular Endothelial Growth Factor A)
Ranibizumab and Aflibercept	Ranibizumab and Aflibercept	Instituto de Olhos de Goiania	marketed	Anti-VEGF agent	VEGF-A (vascular endothelial growth factor-A)
Aflibercept Injection [Eylea]	Aflibercept Injection [Eylea]	Caregen Co. Ltd.	marketed	VEGF inhibitor (soluble decoy receptor)	VEGF-A, VEGF-B, PlGF (Placental Growth Factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF inhibitor class)

1. Hoffmann-La Roche · 2 drugs in this class
2. Genentech, Inc. · 1 drug in this class
3. Genzyme, a Sanofi Company · 1 drug in this class
4. Innostellar Biotherapeutics Co.,Ltd · 1 drug in this class
5. Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
6. Pfizer · 1 drug in this class
7. Eli Lilly and Company · 1 drug in this class
8. Seoul National University Bundang Hospital · 1 drug in this class